The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor
Recruiting
Observational Study
Urothelial Neoplasm
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 210 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The genetic characterization of urothelial tumor disease has brought to light important information about the biology of the disease. The evaluation of molecular DNA markers on tumor tissue could be an approach able to provide important information on the possible aggressiveness of the disease and the sensitivity/resistance profile to drugs commonly adopted in the advanced stage. The main objectiv…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria For the retrospective part:
\- Patients diagnosed with locally advanced operated or metastatic urothelial cancer in follow-up or treatment
Exclusion Criteria For the retrospective part:
\- Deceased patients who have not already performed the NGS analysis from clinical practice.…
Contacts